Matches in Wikidata for { <http://www.wikidata.org/entity/Q64659815> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- Q64659815 description "clinical trial" @default.
- Q64659815 description "ensayu clínicu" @default.
- Q64659815 description "klinisch onderzoek" @default.
- Q64659815 description "клінічне випробування" @default.
- Q64659815 name "A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)" @default.
- Q64659815 type Item @default.
- Q64659815 label "A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)" @default.
- Q64659815 prefLabel "A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)" @default.
- Q64659815 P1132 Q64659815-3503D91C-D933-4BD1-B47A-14CA0E1794A1 @default.
- Q64659815 P131 Q64659815-42BE9368-635B-4266-BB50-818541211A0C @default.
- Q64659815 P1476 Q64659815-C42E183A-7B30-4ED1-993C-09DF8A677022 @default.
- Q64659815 P17 Q64659815-1D31C2EC-6224-4841-840C-30BDD695F1E9 @default.
- Q64659815 P17 Q64659815-1EB75741-2B84-40B1-A439-7CBB76A66645 @default.
- Q64659815 P17 Q64659815-22C145A1-72EB-4C03-BC38-A01FBA2E7E5F @default.
- Q64659815 P17 Q64659815-36C27756-A12D-4F17-B612-2947F9FDC1E7 @default.
- Q64659815 P17 Q64659815-3DE3813D-CF9E-470C-A0DE-AE7F40A95961 @default.
- Q64659815 P17 Q64659815-47766BBF-FA1D-4D6E-B1ED-247AB57BF516 @default.
- Q64659815 P17 Q64659815-58B4D824-FEFD-43A3-A868-CCCF0145029E @default.
- Q64659815 P17 Q64659815-6D566939-E84A-499C-89F5-C136632AC2DB @default.
- Q64659815 P17 Q64659815-8665ED19-25E2-4D4C-9E13-062D5E212A32 @default.
- Q64659815 P17 Q64659815-97472BC1-F350-454D-9954-A51C80A498CC @default.
- Q64659815 P17 Q64659815-A2B76C0C-8732-4C62-BB40-ADE5954777B8 @default.
- Q64659815 P17 Q64659815-AF9C2730-42CD-4590-8B8D-F864F0430864 @default.
- Q64659815 P17 Q64659815-B09DE0EB-CCAD-4175-914E-1EA04B9C8267 @default.
- Q64659815 P17 Q64659815-B312BB10-716B-4ABF-95B6-673F753470C1 @default.
- Q64659815 P17 Q64659815-BD0A5AF4-C0B8-4720-BD2E-38ACFFE43E91 @default.
- Q64659815 P17 Q64659815-C0899420-3EE9-4F31-A2C2-73C923E09155 @default.
- Q64659815 P17 Q64659815-CCF20C88-2430-4F40-8BD8-3433B1D81044 @default.
- Q64659815 P17 Q64659815-CD12C8E3-1F38-4659-98D6-A6439FE70487 @default.
- Q64659815 P17 Q64659815-F820BA92-DFB5-4367-832C-2E9EED0F15C4 @default.
- Q64659815 P2899 Q64659815-C1FDF2F3-40A0-45A8-8991-FFDD55CB3045 @default.
- Q64659815 P3098 Q64659815-0CE0DA8C-CD19-48A8-9C08-E06C27B30AB6 @default.
- Q64659815 P31 Q64659815-BF0425DE-67EB-4F92-9958-F2327A886829 @default.
- Q64659815 P4844 Q64659815-B00E758D-A8B1-450A-8E7D-964B69D7A8E4 @default.
- Q64659815 P580 Q64659815-E7C58E9B-D104-475D-9298-F574C5D49570 @default.
- Q64659815 P582 Q64659815-CD8B0CD4-3D02-45C9-933C-06009F7944C4 @default.
- Q64659815 P6099 Q64659815-373A8130-FDF2-4339-A02D-EFE0E4EC40C7 @default.
- Q64659815 P6153 Q64659815-300EFFF9-140A-4422-9BA9-F164FD6BDF12 @default.
- Q64659815 P6153 Q64659815-37C9D14A-8D95-44D7-89F4-033042ED7DAB @default.
- Q64659815 P6153 Q64659815-50F5F15B-B985-42D1-8B34-4A20FC3E4AD8 @default.
- Q64659815 P6153 Q64659815-A0967461-80FA-4659-AB36-C5E3FC4E627F @default.
- Q64659815 P6153 Q64659815-B2689BF4-01E3-468C-8ACF-2AFAA9DDD600 @default.
- Q64659815 P6153 Q64659815-BDDB1F21-E59F-4364-AB88-5AC908AE3985 @default.
- Q64659815 P6153 Q64659815-BFB81DE1-6FFB-4BF5-9A94-9283D0964431 @default.
- Q64659815 P6153 Q64659815-D5E5696A-85B9-4E93-9ED1-FFCA2FDC1546 @default.
- Q64659815 P6153 Q64659815-F0B632E2-4D8C-40EA-AF82-77AC68FA3AFD @default.
- Q64659815 P8363 Q64659815-C4A8A0B9-4078-447A-9E44-492CC6D7603C @default.
- Q64659815 P859 Q64659815-24CF03F0-6357-4B6A-AAB7-632E73C4594A @default.
- Q64659815 P1132 "+452" @default.
- Q64659815 P131 Q8646 @default.
- Q64659815 P1476 "A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab, in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA)" @default.
- Q64659815 P17 Q142 @default.
- Q64659815 P17 Q145 @default.
- Q64659815 P17 Q155 @default.
- Q64659815 P17 Q16 @default.
- Q64659815 P17 Q183 @default.
- Q64659815 P17 Q191 @default.
- Q64659815 P17 Q218 @default.
- Q64659815 P17 Q224 @default.
- Q64659815 P17 Q28 @default.
- Q64659815 P17 Q29 @default.
- Q64659815 P17 Q31 @default.
- Q64659815 P17 Q36 @default.
- Q64659815 P17 Q38 @default.
- Q64659815 P17 Q40 @default.
- Q64659815 P17 Q414 @default.
- Q64659815 P17 Q419 @default.
- Q64659815 P17 Q55 @default.
- Q64659815 P17 Q869 @default.
- Q64659815 P17 Q96 @default.
- Q64659815 P2899 "+18" @default.
- Q64659815 P3098 "NCT01026142" @default.
- Q64659815 P31 Q30612 @default.
- Q64659815 P4844 Q1998021 @default.
- Q64659815 P580 "2010-01-26T00:00:00Z" @default.
- Q64659815 P582 "2015-05-29T00:00:00Z" @default.
- Q64659815 P6099 Q42824827 @default.
- Q64659815 P6153 Q25188472 @default.
- Q64659815 P6153 Q2553113 @default.
- Q64659815 P6153 Q29480379 @default.
- Q64659815 P6153 Q30293330 @default.
- Q64659815 P6153 Q3145371 @default.
- Q64659815 P6153 Q39988 @default.
- Q64659815 P6153 Q5661215 @default.
- Q64659815 P6153 Q5902953 @default.
- Q64659815 P6153 Q7063615 @default.
- Q64659815 P8363 Q78089383 @default.
- Q64659815 P859 Q212646 @default.